Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
نویسندگان
چکیده
BACKGROUND Prior infection with one strain TB has been linked with diminished likelihood of re-infection by a new strain. This paper attempts to determine the role of declining prevalence of drug-susceptible TB in enabling future epidemics of MDR-TB. METHODS A computer simulation of MDR-TB epidemics was developed using an agent-based model platform programmed in NetLogo (See http://mdr.tbtools.org/). Eighty-one scenarios were created, varying levels of treatment quality, diagnostic accuracy, microbial fitness cost, and the degree of immunogenicity elicited by drug-susceptible TB. Outcome measures were the number of independent MDR-TB cases per trial and the proportion of trials resulting in MDR-TB epidemics for a 500 year period after drug therapy for TB is introduced. RESULTS MDR-TB epidemics propagated more extensively after TB prevalence had fallen. At a case detection rate of 75%, improving therapeutic compliance from 50% to 75% can reduce the probability of an epidemic from 45% to 15%. Paradoxically, improving the case-detection rate from 50% to 75% when compliance with DOT is constant at 75% increases the probability of MDR-TB epidemics from 3% to 45%. CONCLUSIONS The ability of MDR-TB to spread depends on the prevalence of drug-susceptible TB. Immunologic protection conferred by exposure to drug-susceptible TB can be a crucial factor that prevents MDR-TB epidemics when TB treatment is poor. Any single population that successfully reduces its burden of drug-susceptible TB will have reduced herd immunity to externally or internally introduced strains of MDR-TB and can experience heightened vulnerability to an epidemic. Since countries with good TB control may be more vulnerable, their self interest dictates greater promotion of case detection and DOTS implementation in countries with poor control to control their risk of MDR-TB.
منابع مشابه
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
BACKGROUND In South Africa, patients with multi-drug-resistant tuberculosis (MDR-TB) are hospitalised from MDR-TB treatment initiation until culture conversion. Although MDR-TB accounts for <3% of incident TB in South Africa, 55% of the public sector TB budget is spent on MDR-TB. To inform new strategies for MDR-TB management, we estimated the per-patient cost (USD 2011) of inpatient MDR-TB tre...
متن کاملPredictors of Treatment Success for Multidrug Resistant Tuberculosis
After decades of relatively little attention, the field of tuberculosis (TB) research has drawn much attention in recent years. New anti-TB drugs, those already commercially available and others still in the development pipeline, are among the primary drivers of active research, along with commitments from governmental and non-governmental entities for the global eradication of TB. However, man...
متن کاملMinimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa1
Multidrug- (MDR) and extensively drug-resistant tuberculosis (XDR TB) are commonly associated with Beijing strains. However, in KwaZulu-Natal, South Africa, which has among the highest incidence and mortality for MDR and XDR TB, data suggest that non-Beijing strains are driving the epidemic. We conducted a retrospective study to characterize the strain prevalence among drug-susceptible, MDR, an...
متن کاملHIV and multidrug-resistant tuberculosis: overlapping epidemics
People infected with Mycobacterium tuberculosis and HIV are much more likely to develop active tuberculosis (TB) than people with M. tuberculosis but without HIV [1]. Patients infected with multidrugresistant (MDR)-TB (defined as resistance to at least rifampicin and isoniazid, the two most powerful antiTB drugs) require longer, more expensive treatment regimens than drug-susceptible TB, with p...
متن کاملHIV and multidrug-resistant tuberculosis: overlapping epidemics.
People infected with Mycobacterium tuberculosis and HIV are much more likely to develop active tuberculosis (TB) than people with M. tuberculosis but without HIV [1]. Patients infected with multidrugresistant (MDR)-TB (defined as resistance to at least rifampicin and isoniazid, the two most powerful antiTB drugs) require longer, more expensive treatment regimens than drug-susceptible TB, with p...
متن کامل